Patent classifications
C07C237/46
CONTINUOUS CRYSTALLISATION METHOD
The invention provides a method of purifying 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, comprising adding a portion of acid to a stream comprising crude 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide in a solvent and continuously crystallising the 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide from the crude 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, with removal of at least a fraction of the solvent, wherein the crystallisation is carried out in a continuous reactor, wherein the continuous reactor is a plug flow reactor. At least three further portions of acid are added to the continuous reactor during the crystallisation.
CONTINUOUS CRYSTALLISATION METHOD
The invention provides a method of purifying 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, comprising adding a portion of acid to a stream comprising crude 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide in a solvent and continuously crystallising the 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide from the crude 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, with removal of at least a fraction of the solvent, wherein the crystallisation is carried out in a continuous reactor, wherein the continuous reactor is a plug flow reactor. At least three further portions of acid are added to the continuous reactor during the crystallisation.
CONTINUOUS CRYSTALLISATION METHOD
The invention provides a method of purifying 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, comprising adding a portion of acid to a stream comprising crude 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide in a solvent and continuously crystallising the 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide from the crude 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, with removal of at least a fraction of the solvent, wherein the crystallisation is carried out in a continuous reactor, wherein the continuous reactor is a plug flow reactor. At least three further portions of acid are added to the continuous reactor during the crystallisation.
Preparation of ioforminol, an x-ray contrast agent
The present invention relates to a process for the preparation of Ioforminol, a contrast agent useful in X-ray imaging. More particularly, the invention relates to preparation of Ioforminol from a compound mixture comprising 1-formylamino-3,5-bis(2,3-bis(formyloxy)propan-1-ylcarbamoyl)-2,4,6-trioodobenzene by a process comprising in situ hydrolysis and a bis-alkylation.
Preparation of ioforminol, an x-ray contrast agent
The present invention relates to a process for the preparation of Ioforminol, a contrast agent useful in X-ray imaging. More particularly, the invention relates to preparation of Ioforminol from a compound mixture comprising 1-formylamino-3,5-bis(2,3-bis(formyloxy)propan-1-ylcarbamoyl)-2,4,6-trioodobenzene by a process comprising in situ hydrolysis and a bis-alkylation.
Preparation of ioforminol, an x-ray contrast agent
The present invention relates to a process for the preparation of Ioforminol, a contrast agent useful in X-ray imaging. More particularly, the invention relates to preparation of Ioforminol from a compound mixture comprising 1-formylamino-3,5-bis(2,3-bis(formyloxy)propan-1-ylcarbamoyl)-2,4,6-trioodobenzene by a process comprising in situ hydrolysis and a bis-alkylation.
PROCESS OF PREPARING IOSIMENOL
The present invention relates to a 5-step process for preparing iosimenol starting from ammonium 3-amino-5-(aminocarbonyl)benzoate which is first converted to 3-amino-5-(aminocarbonyl)-2,4,6-triiodobenzoic acid using sodium iodine dichloride (NaICl.sub.2). The present invention further relates to processes for purifying iosimenol.
PROCESS OF PREPARING IOSIMENOL
The present invention relates to a 5-step process for preparing iosimenol starting from ammonium 3-amino-5-(aminocarbonyl)benzoate which is first converted to 3-amino-5-(aminocarbonyl)-2,4,6-triiodobenzoic acid using sodium iodine dichloride (NaICl.sub.2). The present invention further relates to processes for purifying iosimenol.
Contrast agents
The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing two linked iodinated phenyl groups of the general formula R—N(CHO)—X—N(R.sup.3)—R wherein X denoted an optionally substituted alkylene group, R.sup.3 denotes a hydrogen atom or an acyl function and each R denotes a triiodinated phenyl residue further substituted by hydrophilic moieties. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging, and to contrast media containing such compounds.
Contrast agents
The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing two linked iodinated phenyl groups of the general formula R—N(CHO)—X—N(R.sup.3)—R wherein X denoted an optionally substituted alkylene group, R.sup.3 denotes a hydrogen atom or an acyl function and each R denotes a triiodinated phenyl residue further substituted by hydrophilic moieties. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging, and to contrast media containing such compounds.